May 8, 2019
IVERIC bio Reports First Quarter 2019 Financial and Operating Results
– Conference Call and Webcast Today, May 8, 2019, at 8:00 a.m. ET – NEW YORK–(BUSINESS WIRE)–IVERIC bio (Nasdaq: ISEE)…
Pharmaceuticals, Biotechnology and Life Sciences
– Conference Call and Webcast Today, May 8, 2019, at 8:00 a.m. ET – NEW YORK–(BUSINESS WIRE)–IVERIC bio (Nasdaq: ISEE)…
— First-Quarter 2019 Net Sales of $280.4 Million Increased 25 Percent; First-Quarter 2019 GAAP Net Loss of $32.9 Million; Adjusted…
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR…
– Initiated Phase 1 Trial for FA “Process B” Using a Modified Cell Enrichment Process, Transduction Enhancers, and Commercial-Grade Vector…
— Companies to Pursue a Human Genetics Approach to Drug Discovery and Development — FOSTER CITY, Calif. & CAMBRIDGE, Mass.–(BUSINESS…
HYDERABAD, India & MORGAN HILL, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Antibodydiscovery?src=hash" target="_blank"gt;#Antibodydiscoverylt;/agt;–GVK BIO is pleased to announce the appointment of Dr. Axel Schleyer…
New class of excipients offers a promising alternative to polysorbates for stabilizing proteins WOBURN, Mass.–(BUSINESS WIRE)–ReForm Biologics, a pharmaceutical technology…
MAINZ, Germany–(BUSINESS WIRE)–BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious…
Fourth-quarter fiscal 2019 revenues of $52.4 billion and full-year fiscal 2019 revenues of $214.3 billion, a full-year increase of 3%.…
Rare Diseases: New development candidate announced for glycogen storage disease type 1a (GSD1a), a rare metabolic disorder; Company now has…